| domain | finding | evidence type/strength | key source |
|---|---|---|---|
| Disease identity | Dilated Cardiomyopathy 1GG is a Mendelian DCM subtype linked to **SDHA**; foundational reported causal variant is **c.1664G>A (p.Gly555Glu / G555E)** in homozygosity | Human primary family study; strong for variant-disease association in reported kindreds | Levitas et al., 2010 (pqac-00000010, pqac-00000011, pqac-00000014) |
| Inheritance | **Autosomal recessive** inheritance in consanguineous families; affected individuals homozygous, available parents typically heterozygous | Human segregation evidence; strong within families | Levitas et al., 2010 (pqac-00000010, pqac-00000011, pqac-00000013) |
| Cohort/founder context | **15 Bedouin patients** from **two large consanguineous families** of one tribe; authors infer a common founder | Human cohort description; moderate-strong | Levitas et al., 2010 (pqac-00000010, pqac-00000011) |
| Onset/clinical spectrum | Onset ranged from **32 weeks gestation to 10 years**; prominent pediatric/neonatal isolated cardiomyopathy with LV dilation and systolic dysfunction | Human case-series evidence; strong descriptive | Levitas et al., 2010 (pqac-00000010, pqac-00000011, pqac-00000012) |
| Core phenotype | Frequent features included **respiratory distress, congestive heart failure, cardiogenic shock, cardiomegaly, LV dilation, reduced fractional shortening**, and **LV noncompaction in 8 infants** | Human phenotype evidence; strong descriptive | Levitas et al., 2010 (pqac-00000011, pqac-00000012) |
| Mortality/course | Condition showed **high mortality**, with **about two-thirds** succumbing to cardiac failure; rapid deterioration resembles mitochondrial cardiomyopathy burden | Human case-series evidence; moderate-strong | Levitas et al., 2010 (pqac-00000014) |
| Cardiac testing | ECG reportedly showed **sinus rhythm, LV hypertrophy, normal QTc**; lactate was usually normal except **mild elevation to 3.7 mmol/L**; two brain MRIs lacked Leigh-syndrome lesions | Human clinical testing evidence; moderate | Levitas et al., 2010 (pqac-00000011) |
| Biochemical defect | Respiratory-chain testing showed **tissue-specific complex II deficiency**: skeletal muscle residual activity about **50-60%**, versus myocardium about **15-18%** for succinate dehydrogenase/complex II; succinate oxidation in muscle **26%** in one assay | Human biochemical evidence; strong | Levitas et al., 2010 (pqac-00000011, pqac-00000013, pqac-00000014) |
| Specificity/variability | Partial complex I decrease occurred in one patient, but normal aconitase argued against generalized iron-sulfur metabolism failure; phenotype showed marked intrafamilial variability | Human biochemical/clinical evidence; moderate | Levitas et al., 2010 (pqac-00000011, pqac-00000014) |
| Reduced penetrance | One adult father was **homozygous** for the variant yet clinically unaffected on exam, ECG, and echocardiography despite reduced lymphoblast complex II activity, indicating **nonpenetrance/reduced penetrance** | Human observation; important but based on single individual | Levitas et al., 2010 (pqac-00000013, pqac-00000014) |
| Mechanistic interpretation | Authors concluded disease is “**presumably caused by the significant tissue-specific reduction in SDH enzymatic activity in the heart muscle**,” while retaining more activity in skeletal muscle and lymphoblastoid cells | Human mechanistic inference anchored by enzyme assays; moderate | Levitas et al., 2010 (pqac-00000010, pqac-00000014) |
| Supporting disease-gene mapping | Independent target-disease aggregation resources also map **SDHA** to dilated/familial isolated DCM | Aggregated database evidence; supportive but secondary | Open Targets association (pqac-00000000) |
| Experimental mechanism relevance | In mice, **cardiac Sdhaf4 loss** impaired complex II assembly, promoted **SDHA/SDHB degradation**, metabolic impairment, **DRP1-mediated mitochondrial fission/mitophagy**, and progressive **dilated cardiomyopathy/lethal heart failure** | Mouse mechanistic study; strong for complex-II-to-DCM biology, indirect for DCM1GG | Wang et al., 2022 (pqac-00000009, pqac-00000007, pqac-00000008) |
| Experimental rescue relevance | In the Sdhaf4 mouse model, **fumarate supplementation** or **mitochondrial fission inhibition** partially restored cardiac function and prolonged lifespan | Mouse interventional evidence; hypothesis-generating, not subtype-specific clinical proof | Wang et al., 2022 (pqac-00000009, pqac-00000007, pqac-00000008) |
| Current diagnosis | Contemporary cardiomyopathy guidance emphasizes **deep phenotyping, ECG, biomarkers, echocardiography/CMR, and genetic workup** for hereditary cardiomyopathy | Recent guideline/review evidence; strong for general DCM practice | ESC-guideline summary 2024; guideline review 2025 (pqac-00000015, pqac-00000006) |
| Current family management | **Genetic counselling and cascade screening** of at-risk relatives are recommended when a pathogenic variant is identified; advanced HF care may require transplant/device evaluation | Recent guideline/review evidence; strong for general DCM practice | Guideline review 2025 (pqac-00000006) |
| Subtype-specific treatment evidence | No **approved therapy**, no validated **SDHA/DCM1GG-specific treatment algorithm**, and no clearly identified **clinical trial dedicated to this subtype** were found in the available evidence | Evidence gap / negative finding from searched literature and trials; moderate confidence | Available evidence corpus and trial searches (pqac-00000006, pqac-00000015) |


*Table: This table compacts the strongest available evidence for Dilated Cardiomyopathy 1GG, separating direct human subtype evidence from indirect mechanistic and guideline evidence. It is useful for quickly identifying what is established, what is inferred, and where current evidence gaps remain.*